World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
37821
World Ranking
9971
National Ranking
5132

Overview

Richard L. Theriault is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research intersects oncology with economic and financial perspectives, focusing on the impacts and risk factors associated with cancer.

The scientist's recent publications cover topics related to cancer research and economics. Notable papers include:

  • EP.04A.08 Leveraging the Quebec Lung Cancer Screening Program to Create a Collaborative Biobanking Project for Research Purposes, 2024, Journal of Thoracic Oncology
  • Abstract P4-14-02: Cohort study of women treated with chemotherapy for breast cancer during pregnancy compared with non-pregnant breast cancer patients, 2020, Cancer Research

Frequently collaborating with other researchers, Richard L. Theriault has worked alongside:

  • Sophie Plante
  • Sabrina Biardel
  • Andrea Mogas
  • Margaret Allard
  • Samuel Martel

Their contributions appear in specialist journals such as:

  • Journal of Thoracic Oncology
  • Cancer Research

Their research fields include oncology and economics and econometrics, reflecting a multidisciplinary approach.

Main topics of investigation in their work are:

  • Economic and Financial Impacts of Cancer
  • Cancer Risks and Factors

Best Publications

  • Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

    S. Eva Singletary;Craig Allred;Pandora Ashley;Lawrence W. Bassett

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames

  • Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

    Frankie Ann Holmes;Ronald S. Walters;Richard L. Theriault;Aman U. Buzdar

  • Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

    Gabriel N. Hortobagyi;Richard L. Theriault;Lester Porter;Douglas Blayney

  • Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

    Allan Lipton;Richard L. Theriault;Gabriel N. Hortobagyi;Joseph Simeone

  • Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel

    Nuhad K. Ibrahim;Neil Desai;Sewa Legha;Patrick Soon-Shiong

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

    Gabriel N. Hortobagyi;Richard L. Theriault;Allan Lipton;Lester Porter

  • The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial

    Jeffrey S. Wefel;Renato Lenzi;L D O Richard Theriault;Robert N. Davis

  • Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial

    Richard L. Theriault;Allan Lipton;Gabriel N. Hortobagyi;Richard Leff

  • Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

    Nancy U. Lin;Ann Vanderplas;Melissa E. Hughes;Richard L. Theriault

  • Breast cancer: Clinical practice guidelines in oncology

    Robert W. Carlson;Benjamin O. Anderson;Harold J. Burstein;Charles E. Cox

  • Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

    Aman U. Buzdar;Vicente Valero;Nuhad K. Ibrahim;Deborah Francis

  • Management of Breast Cancer During Pregnancy Using a Standardized Protocol

    David L. Berry;Richard L. Theriault;Frankie A. Holmes;Valerie M. Parisi

  • High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

    Ana Maria Gonzalez-Angulo;Jennifer K Litton;Kristine R Broglio;Funda Meric-Bernstam

  • Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

    Marjorie C. Green;Aman U. Buzdar;Terry Smith;Nuhad K. Ibrahim

  • Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation

    Angela Katz;Eric A. Strom;Thomas A. Buchholz;Howard D. Thames

  • Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero

    Karin M.E. Hahn;Peter H. Johnson;Nancy Gordon;Henry Kuerer

  • Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

    Vicente Valero;Frankie A. Holmes;Ronald S. Walters;Richard L. Theriault

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Stephen B. Edge
Stephen B. Edge Roswell Park Cancer Institute
Aman U. Buzdar
Aman U. Buzdar The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Jane C. Weeks
Jane C. Weeks Harvard University
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Eric P. Winer
Eric P. Winer Yale University
S. Eva Singletary
S. Eva Singletary The University of Texas MD Anderson Cancer Center
Clifford A. Hudis
Clifford A. Hudis Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring healthcare careers beyond a traditional medical degree, there are several flexible online options to consider. For those interested in advanced practice roles without a nursing background, msn direct entry programs online offer a fast track to becoming a nurse leader, even for non-nursing graduates.

Entry-level nursing pathways are also widely accessible. Many students opt for accredited online adn programs, which provide foundational nursing education with greater flexibility—ideal for those balancing work or family commitments.

Not every healthcare career requires direct patient care. Administrative roles like medical billing and coding are in high demand and can be started quickly. If affordability is a key concern, consider choosing from online medical billing and coding schools that accept fafsa.

Admission processes vary: some nursing schools require prerequisite exams, while others do not. If you’re concerned about entrance tests, you may want to look for programs that answer the question, do you have to take the teas test to get into nursing school.

Best Scientists Citing Richard L. Theriault

Trending Scientists

Recently Published Articles